Anyone who has tried to get Accutane knows the drill: monthly pregnancy tests, two forms of birth control, a seven-day pharmacy pickup window and a bureaucratic program called iPLEDGE that has been known to lock patients out of their prescriptions over a missed click. Now, as reported by Dermatology Times, Clear Health is offering a way around all of it.
The telehealth skin-care platform just launched Isoclear, a prescription topical acne treatment using isotretinoin—the active ingredient in oral Accutane—delivered through a 3-phase compounded regimen. Unlike oral isotretinoin, which requires enrollment in the iPLEDGE risk management program and ongoing laboratory monitoring, Isoclear is formulated as a topical treatment by licensed US compounding pharmacies. Because it is a compounded topical product, it falls entirely outside the iPLEDGE system. The company positions the approach as a more accessible alternative for patients who are candidates for isotretinoin therapy but may be hesitant to pursue the oral formulation, including women of childbearing potential.
Dallas dermatologist Aaron Farberg, MD, said in a news release that isotretinoin has long been one of the most effective therapies available for acne. “What’s new here is the ability to deliver it topically in a personalized formulation, giving patients a targeted approach that can improve tolerability while maintaining clinical impact,” he said.
Patients are connected with licensed dermatologists through Clear Health’s digital platform, who prescribe individualized formulations fulfilled by licensed pharmacies. Formulations are adjusted over time based on patient response. The company reports many patients see results within several weeks.
Three-Phase Treatment Structure
Isoclear is structured across three sequential phases. The first phase, Clear, targets active acne using topical isotretinoin to normalize cell turnover and prevent pore occlusion, combined with topical clindamycin to reduce acne-causing bacteria and inflammation. The company notes clindamycin exposure is intentionally short-term to reduce antibiotic resistance risk. Additional ingredients may be incorporated based on individual patient needs.
The second phase, Fade, addresses post-acne sequelae including hyperpigmentation and uneven skin tone. Topical isotretinoin continues to support cell turnover in this phase alongside tranexamic acid for hyperpigmentation and niacinamide (vitamin B3) for barrier support and redness reduction.
The third phase, Renew, focuses on long-term maintenance and skin quality. Isotretinoin remains in the formulation alongside copper peptide (GHK-Cu), which the company cites for supporting skin repair and improving texture and firmness.
Compounding and Regulatory Considerations
All Isoclear formulations are prepared by licensed US compounding pharmacies operating under applicable USP standards, with active pharmaceutical ingredients sourced from FDA-registered and inspected facilities, according to Jason Lang, PharmD, a Clear Health advisor. Because it is a compounded topical product, Isoclear does not carry FDA approval and falls outside the iPLEDGE system that governs commercially approved oral isotretinoin.
Isoclear is priced at $50 per month, billed as $100 for a two-month supply, with an annual plan available at $40 per month. Three-month supply options are available during the Fade and Renew phases.
Clear Health CEO Michael Chang said the product is intended to expand access to isotretinoin in a format more aligned with contemporary patient preferences. “Oral isotretinoin is highly effective, but it’s not the right fit for every patient,” Chang said. “Isoclear expands access to this gold-standard molecule in a way that’s more flexible, personalized, and aligned with how patients want to receive care today.”
